Multivariate survival analysis including putative prognostic factors such as KPS [31, 32], radiation therapy, chemotherapy, resection extent [33] demonstrated that HOXD4 was an independent prognosis factor in glioma patients. This evidence concerns the gene HOXD4 and central nervous system cancer.